BORTEZOMIB TEVA 1 MG
País: Israel
Idioma: anglès
Font: Ministry of Health
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
BORTEZOMIB
Disponible des:
ABIC MARKETING LTD, ISRAEL
Codi ATC:
L01XX32
formulario farmacéutico:
POWDER FOR SOLUTION FOR INJECTION
Composición:
BORTEZOMIB 1 MG
Vía de administración:
I.V
tipo de receta:
Required
Fabricat per:
TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY
Área terapéutica:
BORTEZOMIB
indicaciones terapéuticas:
Bortezomib Teva is indicated for the treatment of patients with multiple myeloma. Bortezomib Teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Bortezomib Teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
Data d'autorització:
2017-07-04
